Complications of levodopa therapy in Parkinson's disease

被引:2
|
作者
Dubow, Jordan [1 ]
Olanow, C. Warren [2 ]
机构
[1] Avadel Pharmaceut PLC, Chesterfield, MO 63005 USA
[2] Mt Sinai Hlth Syst, Dept Neurol & Neurosci, New York, NY USA
来源
EXPERT OPINION ON ORPHAN DRUGS | 2019年 / 7卷 / 09期
关键词
Parkinson's disease; motor complications; dyskinesia; wearing off; levodopa; EXTENDED-RELEASE CAPSULES; CARBIDOPA INTESTINAL GEL; PLACEBO-CONTROLLED TRIAL; DEEP-BRAIN-STIMULATION; DOUBLE-BLIND; MOTOR FLUCTUATIONS; INDUCED DYSKINESIA; WEARING-OFF; DOPAMINE; ISTRADEFYLLINE;
D O I
10.1080/21678707.2019.1662294
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Levodopa remains the most effective treatment for the motor symptoms of Parkinson's disease (PD). However, with chronic treatment, PD patients develop motor complications, which consist of motor fluctuations and dyskinesia. Many new treatments, both medical and interventional, have been developed for the treatment of motor complications but there continues to be an unmet medical need for further treatments. Areas covered: This manuscript summarizes the phenomenology, pathophysiology, prevalence and current and future treatments of motor complications in PD patients based on a PubMed literature search from 1950s to present. Expert opinion: Motor complications are prevalent in PD and risk factors for developing these complications are well-known and well characterized. There are many effective medical and interventional treatments for both motor fluctuations and dyskinesia in PD patients. Despite these treatments, many patients still suffer from many hours of 'Off' time or dyskinesia that have a profound negative impact on quality of life. There are many exciting treatments under development for motor complications that may provide additional benefit for PD patients.
引用
收藏
页码:391 / 397
页数:7
相关论文
共 50 条
  • [1] Motor complications of chronic levodopa therapy in Parkinson's disease
    Miyawaki, E
    Lyons, K
    Pahwa, R
    Troster, AI
    Hubble, J
    Smith, D
    Busenbark, K
    McGuire, D
    Michalek, D
    Koller, WC
    [J]. CLINICAL NEUROPHARMACOLOGY, 1997, 20 (06) : 523 - 530
  • [2] Parkinson's disease - Levodopa complications
    King, DB
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1999, 26 : S13 - S20
  • [3] Levodopa motor complications in Parkinson's disease
    Obeso, JA
    Olanow, CW
    Nutt, JG
    [J]. TRENDS IN NEUROSCIENCES, 2000, 23 (10) : S2 - S7
  • [4] Embelin and Levodopa Combination Therapy Mitigates Parkinson's Disease Complications in Mice
    Koppal, Anand
    Sivanesan, Senthilkumar
    Ramachandra, Vagdevi Hangarakatte
    Sukumar, Ethirajan
    Vijayaraghavan, Rajagopalan
    [J]. INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH, 2021, 55 (02) : S468 - S478
  • [5] Motor complications of treatment with levodopa in Parkinson's disease
    García-Escrig, M
    Bermejo-Pareja, F
    [J]. REVISTA DE NEUROLOGIA, 1999, 28 (08) : 799 - 809
  • [6] Initiating Levodopa Therapy for Parkinson's Disease
    Olanow, C. Warren
    Kieburtz, Karl
    Stocchi, Fabrizio
    [J]. MOVEMENT DISORDERS, 2014, 29 (03) : 430 - 430
  • [7] The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications
    Kostic, VS
    Marinkovic, J
    Svetel, M
    Stefanova, E
    Przedborski, S
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2002, 9 (01) : 9 - 14
  • [8] Motor complications, levodopa metabolism and progression of Parkinson's disease
    Mueller, Thomas
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (07) : 847 - 855
  • [9] Does combined levodopa and bromocriptine therapy in Parkinson's disease prevent late motor complications?
    Alarcon, F
    Cevallos, N
    Lees, AJ
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 1998, 5 (03) : 255 - 263
  • [10] Asymmetry index as a simple clinical predictor of efficacy and complications of Levodopa therapy of Parkinson's disease
    Rosinskaya, A.
    Vasenina, E.
    Coloman, I.
    Levin, O.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 1125 - 1126